secwatch / observer
8-K filed April 21, 2025, 7:59 PM ET ticker INBP CIK 0001016504
debt confidence high sentiment neutral materiality 0.60

INTEGRATED BIOPHARMA INC (INBP): debt financing — Integrated BioPharma enters $4.5M PNC credit facility; replaces prior debt

INTEGRATED BIOPHARMA INC

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

INTEGRATED BIOPHARMA INC incurred debt of $500,000.00 with PNC Bank, National Association at Daily one-month SOFR plus 250 basis points (2.50%) maturing April 5, 2026.

Principal
$500,000.00
Counterparty
PNC Bank, National Association
Rate
Daily one-month SOFR plus 250 basis points (2.50%)
Maturity
April 5, 2026
Event
incurrence
Exact text from the filing
a Convertible Equipment Line of Credit in an amount in the aggregate at any time outstanding not to exceed $500,000.00 (the "Convertible ELOC")
View on SEC.gov
Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

INTEGRATED BIOPHARMA INC incurred revolving credit of $4,000,000.00 with PNC Bank, National Association at Daily one-month SOFR plus 250 basis points (2.50%) maturing April 5, 2026.

Instrument
revolving credit
Principal
$4,000,000.00
Counterparty
PNC Bank, National Association
Rate
Daily one-month SOFR plus 250 basis points (2.50%)
Maturity
April 5, 2026
Event
incurrence
Exact text from the filing
The Loan Agreement provides a committed revolving line of credit under which the Borrower may request and the Bank will make advances to the Borrower from time to time until April 5, 2026, (the "Expiration Date"), in an aggregate amount outstanding at any time not to exceed $4,000,000.00
View on SEC.gov

Browse all debt financings →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR
accession 0001437749-25-012475
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.